SGP logo

SpyGlass Pharma, Inc. Common Stock

SGP
Healthcare|Biotechnology|US
$36.95
+2.87 (+8.41%)
DCF Value
$2.90
Tangible Book / Share
$6.95
Cash / Share
$7.00

Financials

Financial Snapshot

Market Cap
$1.24B
Enterprise Value
$1.01B
Revenue (TTM)
$0.00
Net Income (TTM)
-$56.1M
Cash & Investments
$234.2M
Net Cash
$232.6M
Free Cash Flow (TTM)
-$49.7M
Operating CF (TTM)
-$46.6M
Debt/Equity
0.01

Cash Runway & Burn Rate

Cash on Hand
$234.2M
Quarterly Burn
$11.6M
Monthly Burn
$3.9M
Est. Runway
~20.1 quarters
MetricTrend2025TTM
Cash & Investments
$107.4M$234.2M
Operating Cash Flow
-$32.7M-$46.6M
Free Cash Flow
-$33.5M-$49.7M
Capital Expenditure
-$789.0K-$3.2M
Financing Cash Flow
$124.6M$156.6M

R&D Spending

R&D (TTM)
$34.7M
R&D Intensity
—
R&D Growth vs Prior
+21.0%
MetricTrend2025TTM
Revenue
$0.00$0.00
R&D Expense
$28.6M$34.7M
SG&A
$12.2M$26.8M

Income Statement

MetricTrend2025TTM
Revenue
$0.00$0.00
Cost of Revenue
$612.0K$875.7K
Gross Profit
-$612.0K-$875.7K
R&D
$28.6M$34.7M
SG&A
$12.2M$26.8M
Operating Income
-$41.4M-$62.1M
Interest Expense
$0.00$0.00
Pretax Income
-$39.9M-$56.1M
Net Income
-$39.9M-$56.1M
EPS (Diluted)
-1.25-1.66
EBITDA
-$39.3M-$58.4M
Shares Out. (M)
31.9133.44

Balance Sheet

MetricTrend2025TTM
Cash & Equivalents
$96.4M$223.1M
Short-Term Investments
$11.1M$11.0M
Total Current Assets
$108.8M$236.5M
Total Assets
$115.9M$243.4M
Total Current Liabilities
$8.6M$9.4M
Long-Term Debt
$0.00$0.00
Total Liabilities
$214.7M$11.1M
Stockholders' Equity
-$98.8M$232.4M
Retained Earnings
-$104.7M-$138.4M

Cash Flow Statement

MetricTrend2025TTM
Operating Cash Flow
-$32.7M-$46.6M
Capital Expenditure
-$789.0K-$3.2M
Free Cash Flow
-$33.5M-$49.7M
Investing Cash Flow
-$11.8M-$14.2M
Financing Cash Flow
$124.6M$156.6M
Issuance of Stock
$170.0K$157.8M
Repurchase of Stock
-$1.4M$0.00
Net Debt Issuance
$0.00$0.00
Stock Based Comp.
$2.8M$1.9M
Net Change in Cash
$80.1M$95.9M

Dilution Tracker

Shares Outstanding
33M
5-Year Share Growth
+0.0%
Stock Issuance (TTM)
$157.8M
MetricTrend2025TTM
Shares Out. (M)
31.9133.44
Change vs Prior %—4.8%
Stock Issuance
$170.0K$157.8M
Stock Repurchase
-$1.4M$0.00
Stock Based Comp.
$2.8M$1.9M

Margins & Profitability

MetricTrend2025TTM
ROE %
40.3%-75.6%
ROA %
-34.4%-23.0%
ROIC %
-38.6%-26.5%

Valuation

P/E (TTM)At Loss
P/S0.00
P/B5.32
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss

Intrinsic Value Models (per share)

DCF Value
$2.90
Tangible Book / Share
$6.95
Net Current Assets / Share
$6.74
Graham Net-Net
$6.69
Cash / Share
$7.00
MetricTrend2025TTM
P/E Ratio
-21.12-22.26
P/S Ratio
0.000.00
P/B Ratio
-8.525.32
EV/EBITDA
-19.05-17.36
EV/Revenue
0.000.00

Analyst Estimates & Quality

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$0.00$0.00$0.00
Net Income-$79.6M-$97.9M-$118.4M
EPS$-2.50$-2.81$-3.06
# Analysts (EPS)444